Disease · MONDO_0004653

atypical chronic myeloid leukemia, BCR-ABL1 negative

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. atypical chronic myeloid leukemia, BCR-ABL1 negative. Diseases, record MONDO_0004653. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004653

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: atypical chronic myeloid leukemia, BCR-ABL1 negative; Open Targets
Open Targets ID: MONDO_0004653; Open Targets
Other names: aCML, atypical CML, atypical chronic myeloid leukaemia, atypical chronic myeloid leukemia, subacute granulocytic leukaemia, subacute granulocytic leukemia, subacute myelogenous leukaemia, subacute myelogenous leukemia, subacute myeloid leukaemia, subacute myeloid leukemia; Open Targets
Disease Ontology: DOID:0060597; Disease Ontology
Disease Ontology: DOID:8747; Disease Ontology
NCI Thesaurus: C3519; NCI Thesaurus
Orphanet: ORPHA:98824; Orphanet
Highest stage of its drugs: Phase 2, for 4 of its 5 drugs, from ClinicalTrials.gov; Open Targets

Drugs5

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
AZACITIDINE	CHEMBL1489	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
RUXOLITINIB PHOSPHATE	CHEMBL1795071	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
DASATINIB	CHEMBL5416410	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
RUXOLITINIB	CHEMBL1789941	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
OXYGEN	CHEMBL1234886	Small molecule	Early phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets8

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
JAK1	Tyrosine-protein kinase JAK1	2	Tyrosine-protein kinase JAK1 inhibitor	Phase 2	https://conductscience.org/library/genes/3716	Drugs and targets
JAK2	Tyrosine-protein kinase JAK2	2	Tyrosine-protein kinase JAK2 inhibitor	Phase 2	https://conductscience.org/library/genes/3717	Drugs and targets
ABL1	Bcr/Abl fusion protein	1	Bcr/Abl fusion protein inhibitor	Phase 2	https://conductscience.org/library/genes/25	Drugs and targets
BCR	Bcr/Abl fusion protein	1	Bcr/Abl fusion protein inhibitor	Phase 2	https://conductscience.org/library/genes/613	Drugs and targets
DNMT1	DNA (cytosine-5)-methyltransferase 1	1	DNA (cytosine-5)-methyltransferase 1 inhibitor	Phase 2	https://conductscience.org/library/genes/1786	Drugs and targets
DNMT3A	DNA (cytosine-5)-methyltransferase 3A	1	DNA (cytosine-5)-methyltransferase 3A inhibitor	Phase 2	https://conductscience.org/library/genes/1788	Drugs and targets
JAK3	Tyrosine-protein kinase JAK3	1	Tyrosine-protein kinase JAK3 inhibitor	Phase 2	https://conductscience.org/library/genes/3718	Drugs and targets
TYK2	Non-receptor tyrosine-protein kinase TYK2	1	Tyrosine-protein kinase TYK2 inhibitor	Phase 2	https://conductscience.org/library/genes/7297	Drugs and targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00255346	Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)	Phase 2	68	2019-05-06	Acute Myeloid Leukemia, Myelodysplastic Syndromes, Agnogenic Myeloid Metaplasia, Myelofibrosis, Hypereosinophilic Syndrome, Polycythemia Vera, Mastocytosis, Leukemia, Myelomonocytic, Chronic	DASATINIB	Its record names the disease	ClinicalTrials.gov
NCT02092324	Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia	Phase 2	51	2020-11-16	Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Neutrophilic Leukemia	RUXOLITINIB PHOSPHATE	Its record names the disease	ClinicalTrials.gov
NCT01787487	Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm	Phase 2	121		Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis	AZACITIDINE, RUXOLITINIB PHOSPHATE	Its record names the disease	ClinicalTrials.gov
NCT05817955	Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN	Phase 2	50		MDS/MPN	AZACITIDINE, RUXOLITINIB	Its record names the disease	ClinicalTrials.gov
NCT03964506	Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant	Early phase 1	24		Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Atypical Chronic Myeloid Leukemia, Chronic Monocytic Leukemia, Myelofibrosis, Myelodysplastic/Myeloproliferative Neoplasm	OXYGEN	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials5

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31880950	RESULT	1	PubMed
42304430	DERIVED	1	PubMed
30185431	DERIVED	1	PubMed
29134664	DERIVED	1	PubMed
25180155	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004653

GET https://conductscience.org/api/diseases/v1/MONDO_0004653/drugs

API reference For AI assistants